Evobrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis (RRMS). According to Globaldata, it is involved in 22 clinical trials, of which 16 were completed, 3 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Evobrutinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Evobrutinib is expected to reach an annual total of $77 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Evobrutinib (M-2951) is under development for the treatment of relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis with relapses. The drug candidate is administered through oral route in the form of capsule or tablet. It is a new chemical entity. The drug candidate acts by targeting bruton's tyrosine kinase (BTK). It was also under development for the treatment of rheumatoid arthritis and systemic lupus erythematosus.
Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.
For a complete picture of Evobrutinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.